ArticleFrontiers in endocrinology2026
Visit-to-visit HbA1c variability and subsequent renal function decline in older adults with type 2 diabetes.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Visit-to-visit HbA1c variability may capture glycemic instability beyond mean HbA1c. We assessed its association with subsequent renal function decline in older Chinese adults with type 2 diabetes. Methods: In a single-center prospective landmark cohort, we enrolled adults with type 2 diabetes who were aged ≥65 years. Index diabetes-care encounters were prospectively identified in 2015-2019. HbA1c variability was calculated from at least three HbA1c measurements collected during a fixed 24-month exposure window, and participants were followed from the 24-month landmark. The primary exposure was the HbA1c coefficient of variation (HbA1c-CV). The primary outcome was sustained renal function decline after a landmark, defined as confirmed ≥20% eGFR decline, eGFR <15 mL/min/1.73 m Results: The cohort included 630 participants (mean age 72.9 years; 52.7% men). During a median of 4.6 years of follow-up, 247 primary renal events occurred. Each 5% absolute increase in HbA1c-CV was associated with higher renal decline risk (HR 1.19, 95% CI 1.08-1.31; Conclusions: Greater visit-to-visit HbA1c variability was independently associated with subsequent renal function decline. HbA1c variability may represent a pragmatic prognostic signal; however, incremental predictive value beyond established kidney markers was not tested in this study.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.